Jupiter Neurosciences announces commercial launch of Nugevia

Jupiter Neurosciences (JUNS) announced the official commercial launch of Nugevia, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter’s strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia’s debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter’s proprietary JOTROL micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. Nugevia’s first three formulations-targeting mitochondrial support, mental clarity, and “beauty from within”-will be sold via a direct-to-consumer model starting in Q3 2025. Each product integrates JOTROL, Jupiter’s enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL is also the foundation of Jupiter’s ongoing therapeutic programs in Parkinson’s and Alzheimer’s disease.